HealthLynked Corp
HLYKDrugs in Pipeline
4
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How HLYK's past catalysts played out
Estradiol transdermal one 90 μL spray
Hot Flashes
Bevasiranib
Macular Degeneration
Abaloparatide Transdermal (50 mcg)
Post Menopausal Osteoporosis
VeraCept
Contraception
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Estradiol transdermal one 90 μL spray | Phase 3 | Hot Flashes | - | - |
Bevasiranib | Phase 2 | Macular Degeneration | - | - |
Abaloparatide Transdermal (50 mcg) | Phase 2 | Post Menopausal Osteoporosis | - | - |
VeraCept | Phase 2 | Contraception | - | - |
Frequently asked questions
What is in HealthLynked Corp's drug pipeline?→
CatalystAlert tracks 4 drug candidates in HealthLynked Corp's (HLYK) pipeline across Phase 3, Phase 2. Its lead program is Estradiol transdermal one 90 μL spray (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is HealthLynked Corp's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for HealthLynked Corp (HLYK) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track HLYK biotech catalysts?→
Add HLYK to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow HealthLynked Corp's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.